FindTrial
Sign In

MicroRNA is involved in the mechanism of myocardial fibrosis in hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy myocardial fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021706
Enrollment
Unknown
Registered
2019-03-05
Start date
2019-03-10
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic obstructive myocardium

Interventions

HOCM:NO

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The diagnosis of hypertrophic cardiomyopathy (HCM) was based on the presence of a hypertrophied myocardial wall (usually =15 mm in adults or the equivalent relative to body surface area in children), as identified by echocardiography, and the absence of other cardiac or systemic diseases that cause hypertrophy, in accordance with the European Society of Cardiology (ESC) Guidelines on diagnosis and management of HCM.

Exclusion criteria

Exclusion criteria: 1. Suffered from other cardiac diseases that can lead to hypertrophy, such as hypertension; 2. Patient has a extremely bad condition and can not tolerate the operation.

Design outcomes

Primary

MeasureTime frame
myocardial fibrosis;—

Countries

China

Contacts

Public ContactKe Lin

West China Hospital, Sichuan University

hdr110828@163.com+86 18602824875

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026